Skip to main content
T

Triviumvet

The startup develops veterinary pharmaceuticals, medical devices, and diagnostics specifically for dogs suffering from untreated health conditions. By providing targeted treatments, the company enhances the quality of life for pets that have been frequently overlooked in veterinary care.

Waterford, United States
Updated 2 months ago

Funding

$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Many companion animals suffer from serious health conditions for which there are limited or unsatisfactory treatment options. This can significantly impact the pet's quality of life and the relationship between pets and their owners. Current veterinary treatments may not always address the underlying causes of these conditions or provide adequate relief.

Solution

TriviumVet is a veterinary pharmaceutical company focused on developing innovative therapeutics for cats and dogs with unmet medical needs. The company's pipeline includes treatments for chronic conditions such as feline hypertrophic cardiomyopathy (HCM), feline chronic kidney disease (CKD), canine neuropathic pain, and gastric ulceration in dogs. TriviumVet utilizes platforms like mTOR inhibition to target the underlying mechanisms of disease and improve treatment outcomes. By developing novel therapies and participating in clinical research, TriviumVet aims to raise the standard of care for pets and enhance their quality of life.

Target Audience

The primary target audience includes veterinarians and pet owners seeking advanced treatment options for serious and chronic conditions affecting their cats and dogs.

Features

  • TRIV202: An mTOR inhibition platform under development for chronic conditions in cats and dogs, including HCM, CKD, cardiomyopathy, and age-related decline.
  • TRIV201: A novel, beef-flavored painkiller under development for canine neuropathic pain.
  • TRIV209: A veterinary proton pump inhibitor under development for the treatment of gastric ulceration in dogs.
  • Clinical trials: Dedicated to advancing veterinary medicine through rigorous clinical research and collaboration.
This profile is AI-generated and may contain inaccuracies.